Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Anal Bioanal Chem ; 416(12): 2969-2981, 2024 May.
Article in English | MEDLINE | ID: mdl-38488952

ABSTRACT

Oral endocrine therapies (OET) for breast cancer treatment need to be taken over a long period of time and are associated with considerable side effects. Therefore, adherence to OET is an important issue and of high clinical significance for breast cancer patients' caregivers. We hypothesized that a new bioanalytical strategy based on liquid chromatography and high-resolution mass spectrometry might be suitable for unbiased adherence monitoring (AM) of OET. Four different biomatrices (plasma, urine, finger prick blood by volumetric absorptive microsampling (VAMS), oral fluid (OF)) were evaluated regarding their suitability for AM of the OET abemaciclib, anastrozole, exemestane, letrozole, palbociclib, ribociclib, tamoxifen, and endoxifen. An analytical method was developed and validated according to international recommendations. The analytical procedures were successfully validated in all sample matrices for most analytes, even meeting requirements for therapeutic drug monitoring. Chromatographic separation of analytes was achieved in less than 10 min and limits of quantification ranged from 1 to 1000 ng/mL. The analysis of 25 matching patient samples showed that AM of OET is possible using all four matrices with the exception of, e.g., letrozole and exemestane in OF. We were able to show that unbiased bioanalytical AM of OET was possible using different biomatrices with distinct restrictions. Sample collection of VAMS was difficult in most cases due to circulatory restraints and peripheral neuropathy in fingers and OF sampling was hampered by dry mouth syndrome in some cases. Although parent compounds could be detected in most of the urine samples, metabolites should be included when analyzing urine or OF. Plasma is currently the most suitable matrix due to available reference concentrations.


Subject(s)
Antineoplastic Agents, Hormonal , Breast Neoplasms , Drug Monitoring , Humans , Female , Breast Neoplasms/drug therapy , Antineoplastic Agents, Hormonal/blood , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Agents, Hormonal/urine , Drug Monitoring/methods , Chromatography, Liquid/methods , Administration, Oral , Mass Spectrometry/methods , Letrozole/blood , Medication Adherence , Limit of Detection , Tamoxifen/therapeutic use , Tamoxifen/blood , Tamoxifen/analysis , Tamoxifen/urine , Saliva/chemistry , Androstadienes/urine , Androstadienes/analysis , Androstadienes/administration & dosage , Androstadienes/therapeutic use , Androstadienes/blood , Anastrozole , Reproducibility of Results
2.
Pharmacol Res Perspect ; 8(5): e00646, 2020 10.
Article in English | MEDLINE | ID: mdl-32813313

ABSTRACT

In previous studies, steady-state Z-endoxifen plasma concentrations (ENDOss) correlated with relapse-free survival in women on tamoxifen (TAM) treatment for breast cancer. ENDOss also correlated significantly with CYP2D6 genotype (activity score) and CYP2D6 phenotype (dextromethorphan test). Our aim was to ascertain which method for assessing CYP2D6 activity is more reliable in predicting ENDOss. The study concerned 203 Caucasian women on tamoxifen-adjuvant therapy (20 mg q.d.). Before starting treatment, CYP2D6 was genotyped (and activity scores computed), and the urinary log(dextromethorphan/dextrorphan) ratio [log(DM/DX)] was calculated after 15 mg of oral dextromethorphan. Plasma concentrations of TAM, N-desmethyl-tamoxifen (ND-TAM), Z-4OH-tamoxifen (4OH-TAM) and ENDO were assayed 1, 4, and 8 months after first administering TAM. Multivariable regression analysis was used to identify the clinical and laboratory variables predicting log-transformed ENDOss (log-ENDOss). Genotype-derived CYP2D6 phenotypes (PM, IM, NM, EM) and log(DM/DX) correlated independently with log-ENDOss. Genotype-phenotype concordance was almost complete only for poor metabolizers, whereas it emerged that 34% of intermediate, normal, and ultrarapid metabolizers were classified differently based on log(DM/DX). Multivariable regression analysis selected log(DM/DX) as the best predictor, with patients' age, weak inhibitor use, and CYP2D6 phenotype decreasingly important: log-ENDOss = 0.162 - log(DM/DX) × 0.170 + age × 0.0063 - weak inhibitor use × 0.250 + IM × 0.105 + (NM + UM) × 0.210; (R2  = 0.51). In conclusion, log(DM/DX) seems superior to genotype-derived CYP2D6 phenotype in predicting ENDOss.


Subject(s)
Breast Neoplasms/drug therapy , Cytochrome P-450 CYP2D6/genetics , Cytochrome P-450 CYP2D6/metabolism , Dextromethorphan/administration & dosage , Tamoxifen/administration & dosage , Administration, Oral , Adult , Aged , Aged, 80 and over , Breast Neoplasms/blood , Breast Neoplasms/genetics , Breast Neoplasms/urine , Chemotherapy, Adjuvant , Dextromethorphan/blood , Dextromethorphan/urine , Female , Genotyping Techniques , Humans , Middle Aged , Tamoxifen/analogs & derivatives , Tamoxifen/blood , Tamoxifen/pharmacokinetics , Tamoxifen/urine
3.
J Pharm Biomed Anal ; 156: 147-152, 2018 Jul 15.
Article in English | MEDLINE | ID: mdl-29704771

ABSTRACT

Antiestrogenic compounds such as tamoxifen, toremifen and chlomifen are used illegally by athletes to minimize physical impacts such as gynecomastia resulting from the secondary effects of anabolic androgenic steroids, used to increase athletic efficiency unlawfully. The use of these compounds is banned by the World Anti-Doping Agency (WADA) and controls are made through analytical methodologies such as HPLC-MS/MS, which do not fulfil the sample throughput requirements. Moreover, compounds such as tamoxifen are also used to treat hormone receptor-positive breast cancer (ER + ).Therapeutic drug monitoring (TDM) of tamoxifen may also be clinically useful for guiding treatment decisions. An accurate determination of these drugs requires a solid phase extraction of patient serum followed by HPLC-MS/MS. In the context of an unmet need of high-throughput screening (HTS) and quantitative methods for antiestrogenic substances we have approached the development of antibodies and an immunochemical assay for the determination of these antiestrogenic compounds. The strategy applied has taken into consideration that these drugs are metabolized and excreted in urine as the corresponding 4-hydroxylated compounds. A microplate-based ELISA procedure has been developed for the analysis of these metabolites in urine with a LOD of 0.15, 0.16 and 0.63 µg/L for 4OH-tamoxifen, 4OH-toremifen and 4OH-clomifen, respectively, much lower than the MRPL established by WADA (20 µg/L).


Subject(s)
Doping in Sports/prevention & control , Drug Monitoring/methods , Selective Estrogen Receptor Modulators/urine , Testosterone Congeners/urine , Breast Neoplasms/drug therapy , Chromatography, High Pressure Liquid , Clomiphene/metabolism , Clomiphene/therapeutic use , Clomiphene/urine , Enzyme-Linked Immunosorbent Assay , Female , Healthy Volunteers , High-Throughput Screening Assays/methods , Humans , Selective Estrogen Receptor Modulators/metabolism , Selective Estrogen Receptor Modulators/therapeutic use , Solid Phase Extraction , Tamoxifen/analogs & derivatives , Tamoxifen/metabolism , Tamoxifen/therapeutic use , Tamoxifen/urine , Tandem Mass Spectrometry , Toremifene/metabolism , Toremifene/therapeutic use , Toremifene/urine
4.
Biomed Chromatogr ; 29(8): 1220-8, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25611330

ABSTRACT

Tamoxifen (TMX) is a nonsteroidal estrogen antagonist drug used for the treatment of breast cancer. It is also included in the list of banned substances of the World Anti Doping Agency (WADA) prohibited in and out of competition. In this work, the excretion of urinary metabolites of TMX after a single therapeutic dose administration in rats has been studied using ultra-high-performance liquid chromatography electrospray time-of-flight mass spectrometry (UHPLC-TOFMS). A systematic strategy based on the search of typical biotransformations that a xenobiotic can undergo in living organisms, based on their corresponding molecular formula modification and accurate mass shifts, was applied for the identification of TMX metabolites. Prior to UHPLC-TOFMS analyses, a solid-phase extraction step with polymeric cartridges was applied to urine samples. Up to 38 TMX metabolites were detected. Additional collision induced dissociation (CID) MS/MS fragmentation was performed using UHPLC-QTOFMS. Compared with recent previous studies in human urine and plasma, new metabolites have been reported for the first time in urine. Metabolites identified in rat urine include the oxygen addition, owing to different possibilities for the hydroxylation of the rings in different positions (m/z 388.2271), the incorporation of two oxygen atoms (m/z 404.2220) (including dihydroxylated derivatives or alternatives such as epoxidation plus hydroxylation or N-oxidation and hydroxylation), epoxide formation or hydroxylation and dehydrogenation [m/z 386.2114 (+O -H2 )], hydroxylation of the ring accompanied by N-desmethylation (m/z 374.2115), combined hydroxylation and methoxylation (m/z 418.2377), desaturated TMX derivate (m/z 370.2165) and its N-desmethylated derivate (m/z 356.2009), the two latter modifications not previously being reported in urine. These findings confirm the usefulness of the proposed approach based on UHPLC-TOFMS.


Subject(s)
Antineoplastic Agents, Hormonal/metabolism , Antineoplastic Agents, Hormonal/urine , Tamoxifen/metabolism , Tamoxifen/urine , Tandem Mass Spectrometry/methods , Animals , Chromatography, High Pressure Liquid/methods , Male , Rats, Wistar
5.
J Mass Spectrom ; 49(7): 570-8, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25044841

ABSTRACT

In this study, tamoxifen metabolic profiles were investigated carefully. Tamoxifen was administered to two healthy male volunteers and one female patient suffering from breast cancer. Urinary extracts were analyzed by liquid chromatography quadruple time-of-flight mass spectrometry using full scan and targeted MS/MS techniques with accurate mass measurement. Chromatographic peaks for potential metabolites were selected by using the theoretical [M + H](+) as precursor ion in full-scan experiment and m/z 72, 58 or 44 as characteristic product ions for N,N-dimethyl, N-desmethyl and N,N-didesmethyl metabolites in targeted MS/MS experiment, respectively. Tamoxifen and 37 metabolites were detected in extraction study samples. Chemical structures of seven unreported metabolites were elucidated particularly on the basis of fragmentation patterns observed for these metabolites. Several metabolic pathways containing mono- and di-hydroxylation, methoxylation, N-desmethylation, N,N-didesmethylation, oxidation and combinations were suggested. All the metabolites were detected in the urine samples up to 1 week.


Subject(s)
Chromatography, Liquid/methods , Tamoxifen/metabolism , Tamoxifen/urine , Tandem Mass Spectrometry/methods , Breast Neoplasms/drug therapy , Doping in Sports , Female , Humans , Male , Tamoxifen/chemistry , Tamoxifen/therapeutic use
6.
Anal Bioanal Chem ; 405(16): 5467-87, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23604525

ABSTRACT

The use of selective oestrogen receptor modulators has been prohibited since 2005 by the World Anti-Doping Agency regulations. As they are extensively cleared by hepatic and intestinal metabolism via oxidative and conjugating enzymes, a complete investigation of their biotransformation pathways and kinetics of excretion is essential for the anti-doping laboratories to select the right marker(s) of misuse. This work was designed to characterize the chemical reactions and the metabolizing enzymes involved in the metabolic routes of clomiphene, tamoxifen and toremifene. To determine the biotransformation pathways of the substrates under investigation, urine samples were collected from six subjects (three females and three males) after oral administration of 50 mg of clomiphene citrate or 40 mg of tamoxifen or 60 mg of toremifene, whereas the metabolizing enzymes were characterized in vitro, using expressed cytochrome P450s and uridine diphosphoglucuronosyltransferases. The separation, identification and determination of the compounds formed in the in vivo and in vitro experiments were carried out by liquid chromatography coupled with mass spectrometry techniques using different acquisition modes. Clomiphene, tamoxifen and toremifene were biotransformed to 22, 23 and 18 metabolites respectively, these phase I reactions being catalyzed mainly by CYP3A4 and CYP2D6 isoforms and, to a lesser degree, by CYP3A5, CYP2B6, CYP2C9, CYP2C19 isoforms. The phase I metabolic reactions include hydroxylation in different positions, N-oxidation, dehalogenation, carboxylation, hydrogenation, methoxylation, N-dealkylation and combinations of them. In turn, most of the phase I metabolites underwent conjugation reaction to form the corresponding glucuro-conjugated mainly by UGT1A1, UGT1A3, UGT1A4, UGT2B7, UGT2B15 and UGT2B17 isoenzymes.


Subject(s)
Chromatography, Liquid/methods , Clomiphene/pharmacokinetics , Tamoxifen/pharmacokinetics , Tandem Mass Spectrometry/methods , Toremifene/pharmacokinetics , Aryl Hydrocarbon Hydroxylases/metabolism , Biotransformation , Clomiphene/metabolism , Clomiphene/urine , Cytochrome P-450 CYP2B6 , Cytochrome P-450 CYP2C19 , Cytochrome P-450 CYP2C9 , Cytochrome P-450 CYP2D6/metabolism , Cytochrome P-450 CYP3A/metabolism , Dealkylation , Doping in Sports , Female , Glucuronosyltransferase/metabolism , Humans , Hydroxylation , Male , Microsomes, Liver/metabolism , Oxidation-Reduction , Oxidoreductases, N-Demethylating/metabolism , Tamoxifen/metabolism , Tamoxifen/urine , Toremifene/metabolism , Toremifene/urine
7.
Rapid Commun Mass Spectrom ; 24(6): 749-60, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20187079

ABSTRACT

Different liquid chromatographic/tandem mass spectrometric (LC/MS/MS) scanning techniques were considered for the characterization of tamoxifene metabolites in human urine for anti-doping purpose. Five different LC/MS/MS scanning methods based on precursor ion scan (precursor ion scan of m/z 166, 152 and 129) and neutral loss scan (neutral loss of 72 Da and 58 Da) in positive ion mode were assessed to recognize common ions or common losses of tamoxifene metabolites. The applicability of these methods was checked first by infusion and then by the injection of solution of a mixture of reference standards of four tamoxifene metabolites available in our laboratory. The data obtained by the analyses of the mixture of the reference standards showed that the five methods used exhibited satisfactory results for all tamoxifene metabolites considered at a concentration level of 100 ng/mL, whereas the analysis of blank urine samples spiked with the same tamoxifene metabolites at the same concentration showed that the neutral loss scan of 58 Da lacked sufficient specificity and sensitivity. The limit of detection in urine of the compounds studied was in the concentration range 10-100 ng/mL, depending on the compound structure and on the selected product ion. The suitability of these approaches was checked by the analysis of urine samples collected after the administration of a single dose of 20 mg of tamoxifene. Six metabolites were detected: 4-hydroxytamoxifene, 3,4-dihydroxytamoxifene, 3-hydroxy-4-methoxytamoxifene, N-demethyl-4-hydroxytamoxifene, tamoxifene-N-oxide and N-demethyl-3-hydroxy-4-methoxytamoxifene, which is in conformity to our previous work using a time-of-flight (TOF) mass spectrometer in full scan acquisition mode.


Subject(s)
Chromatography, Liquid/methods , Tamoxifen/urine , Tandem Mass Spectrometry/methods , Adult , Female , Humans , Male , Reproducibility of Results , Selective Estrogen Receptor Modulators/metabolism , Selective Estrogen Receptor Modulators/urine , Sensitivity and Specificity , Tamoxifen/analogs & derivatives , Tamoxifen/metabolism
8.
J Clin Oncol ; 27(21): 3423-9, 2009 Jul 20.
Article in English | MEDLINE | ID: mdl-19487384

ABSTRACT

PURPOSE Recently, a 36-kDa variant of estrogen receptor alpha (ER-alpha66), ER-alpha36, has been identified and cloned. ER-alpha36 predominantly localizes on the plasma membrane and in the cytoplasm and mediates a membrane-initiated "nongenomic" signaling pathway. Here, we investigate the association between ER-alpha36 expression and tamoxifen resistance in patients with breast cancer. PATIENTS AND METHODS ER-alpha36 protein expression in tumors from 896 women (two independent cohorts, 1 and 2) with operable primary breast cancer was assessed using an immunohistochemistry assay. Results In the first cohort of 710 consecutive patients, overexpression of ER-alpha36 was associated with poorer disease-free survival (DFS) and disease-specific survival (DSS) in patients with ER-alpha66-positive tumors who received tamoxifen treatment (chemotherapy plus tamoxifen or tamoxifen alone, n = 307). In contrast, ER-alpha36 was not associated with survival in patients with ER-alpha66-positive tumors who did not receive tamoxifen (chemotherapy alone, n = 129) and in patients with ER-alpha66-negative tumors whether they received tamoxifen (n = 73) or not (n = 149). In the second cohort of 186 patients who only received tamoxifen as adjuvant therapy, overexpression of ER-alpha36 was significantly associated with poorer DFS and DSS in 156 ER-alpha66-positive patients from this cohort, and ER-alpha36 remained an independent unfavorable factor for both DFS and DSS in these 156 patients by a multivariate analysis (DFS: hazard ratio [HR] = 5.47; 95% CI, 1.81 to 16.51; P =. 003; DSS: HR = 13.97; 95% CI, 1.58 to 123.53; P = .018). CONCLUSION Women with ER-alpha66-positive tumors that also express high levels of ER-alpha36 are less likely to benefit from tamoxifen treatment.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Estrogen Receptor alpha/metabolism , Tamoxifen/therapeutic use , Tamoxifen/urine , Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Cohort Studies , Disease-Free Survival , Drug Resistance, Neoplasm/physiology , Estrogen Receptor alpha/genetics , Female , Gene Expression , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Lymphatic Metastasis/prevention & control , Postmenopause/metabolism
9.
Eur J Mass Spectrom (Chichester) ; 14(3): 171-80, 2008.
Article in English | MEDLINE | ID: mdl-18708697

ABSTRACT

In this paper, we discuss the capabilities of liquid chromatography coupled to mass spectrometry with a time-of flight system with accurate mass measurement for the detection and characterisation of drug metabolites in biological samples for anti-doping purpose. Urinary excretion samples of three selective oestrogen receptor modulators (SERMs) with a common triphenylethylene structure: clomiphene, toremifene, and tamoxifen, obtained after oral administration of a single dose of each drug, were analysed using a time-of-flight system, after automatic tuning and calibration of the equipment, in positive full scan mode using an electrospray ionisation source. Following this approach we detected most of all significant metabolites reported by others and postulated new metabolites, especially for toremifene, have been characterised: N-demethyl-3-hydroxy-4-methoxy-toremifene and 3- hydroxy-4-methoxy-toremifene; in addtiona to this, in the urinary excretion samples of toremifene some metabolites, without the characteristic chlorine isotope pattern, discarded in previous studies, that are also metabolites of tamoxifen, were identified. The lack of certified reference materials does not allow an accurate determination of the limit of detection (LODs) of all metabolites; however an estimation taking into account the response factor of similar compounds allows to estimate that all metabolites are clearly detectable in a range of concentration comprised between 10 ng mL(-1) and 30 ng mL(-1).


Subject(s)
Clomiphene/urine , Selective Estrogen Receptor Modulators/urine , Spectrometry, Mass, Electrospray Ionization/methods , Substance Abuse Detection/methods , Tamoxifen/urine , Toremifene/urine , Adult , Chromatography, High Pressure Liquid , Doping in Sports , Humans , Spectrometry, Mass, Electrospray Ionization/instrumentation
10.
J Chromatogr A ; 1196-1197: 81-8, 2008 Jul 04.
Article in English | MEDLINE | ID: mdl-18538333

ABSTRACT

A molecular imprinted polymer (MIP) has been synthesized in order to specifically extract tamoxifen, a nonsteroidal antiestrogen, and its metabolites from urine by solid-phase extraction (SPE) before HPLC-UV analysis. Clomiphene, a chlorinated tamoxifen analogue, was selected as template for MIP synthesis. Polymerisation was achieved by thermal polymerisation of methacrylic acid (MAA) as functional monomer, ethylene glycol dimethacrylate (EDMA) as cross-linking agent and acetonitrile as porogen. The efficient elimination of the urinary matrix has been obtained by MIP-SPE but the elution recovery of tamoxifen was initially too low ( approximately 14%). This problem has been overcome following two ways. At first, a preliminary HLB-SPE of the urine has enabled to discard endogenous salts and to percolate an organic sample through the MIP cartridge. Extraction recoveries are equal to 56 and 74% for tamoxifen and 4-hydroxytamoxifen, respectively. Then, a second MIP has been prepared with styrene and MAA as functional co-monomers. Strong pi-pi interactions occurring between phenyl groups of styrene and tamoxifen promote rebinding of the analyte by the specific sites. The enhanced hydrophobic character of the imprinted polymer has enabled the direct percolation of urine through MIP-SPE and the easy elimination of endogenous salts from urine with only one aqueous washing step. HPLC-UV analysis has confirmed high extraction recoveries (85%) for tamoxifen and its metabolite with an enrichment factor of 8. This analytical protocol can selectively detect the presence of tamoxifen metabolites in urines and be useful as a proof of doping in competitive sports.


Subject(s)
Chromatography, High Pressure Liquid/methods , Doping in Sports/prevention & control , Polymers/chemistry , Spectrophotometry, Ultraviolet/methods , Tamoxifen/urine , Humans , Molecular Imprinting , Molecular Structure , Polymers/isolation & purification , Reproducibility of Results , Tamoxifen/isolation & purification , Tamoxifen/metabolism
11.
Anticancer Res ; 25(6C): 4487-92, 2005.
Article in English | MEDLINE | ID: mdl-16334131

ABSTRACT

The selective oestrogen-receptor modulator tamoxifen is the most commonly used drug against breast cancer. It has potent metabolites, such as 4-hydroxytamoxifen. Recently, the metabolite 4-hydroxy-N-desmethyltamoxifen has received increased attention as it may be a major contributor to the overall effects of tamoxifen. The excretion of tamoxifen and its metabolites was examined in a patient with biliary drainage after an oral dose of [14C]tamoxifen. During the first 10 days after oral dosing, 11.5, 26.7 and 24.7% of the radioactivity was excreted in the bile, urine and faeces, respectively. After deconjugation with beta-glucuronidase, the concentrations of tamoxifen and 4 of its metabolites were measured, and it was observed that the hydroxylated metabolites were excreted in the bile and urine. 4-Hydroxytamoxifen was the dominant compound, being detected during the first day of observation, whereas 4-hydroxy-N-desmethyltamoxifen was first observed in the urine and bile after 4 days. This is the first report on tamoxifen excretion in human bile and urine demonstrating that 4-hydroxytamoxifen may be a first-pass metabolite. In contrast, the potent metabolite 4-hydroxy-N-desmethyltamoxifen was first detected 4 days after administration of a single oral dose.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacokinetics , Bile/metabolism , Pancreatic Neoplasms/metabolism , Tamoxifen/analogs & derivatives , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Agents, Hormonal/urine , Feces/chemistry , Female , Humans , Middle Aged , Pancreatic Neoplasms/urine , Tamoxifen/pharmacokinetics , Tamoxifen/therapeutic use , Tamoxifen/urine
12.
Luminescence ; 20(4-5): 315-20, 2005.
Article in English | MEDLINE | ID: mdl-16134199

ABSTRACT

The reaction between soluble Mn(IV) and tamoxifen can produce chemiluminescence and formaldehyde can enhance this chemiluminescence reaction. A tamoxifen molecular imprinted polymer (MIP) was synthesized and its adsorption selectivity to tamoxifen in aqueous solution was evaluated. Using a synthesized tamoxifen MIP as the recognition material and a soluble Mn(IV)-formaldehyde-tamoxifen chemiluminesence system as the detection system, a new molecule imprinting-chemiluminesence method of determination of tamoxifen was established. The response range of this method was 1.0 x 10(-7)-6.0 x 10(-6) g/mL, with a linear correlation coefficient of 0.997. The detection limit was 4 x 10(-8) g/mL. The relative standard deviation for 5.0 x 10(-7) g/mL tamoxifen solution was 4.1% (n = 9).


Subject(s)
Breast Neoplasms/urine , Luminescent Measurements/methods , Polymers/chemistry , Tamoxifen/chemistry , Tamoxifen/urine , Adsorption , Formaldehyde , Humans , Manganese/chemistry , Molecular Structure , Solutions/chemistry , Time Factors
13.
Electrophoresis ; 22(13): 2730-6, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11545399

ABSTRACT

Tamoxifen is an antiestrogen drug used to treat breast cancer. We have extracted tamoxifen and several of its metabolites from urine of patients with both metastatic (stage IV) and locally confined (stages I, II, and III) breast cancer. Analysis of these metabolites was performed by nonaqueous capillary electrophoresis with electrospray-mass spectrometry. Peak heights from extracted ion current electropherograms of the metabolites were used to establish a metabolic profile for each patient. We demonstrate substantial variation among patient profiles, statistically significant differences in the amount of urinary tamoxifen N-oxide found in stages I, II, and III compared to stage IV breast cancer patients, and statistically significant differences in the amount of 3,4-dihydroxytamoxifen found in progressors compared to nonprogressors with metastatic (stage IV) cancer.


Subject(s)
Antineoplastic Agents, Hormonal/urine , Breast Neoplasms/urine , Carcinoma, Ductal, Breast/urine , Electrophoresis, Capillary/methods , Estrogen Antagonists/urine , Spectrometry, Mass, Electrospray Ionization/methods , Tamoxifen/urine , Adult , Aged , Aged, 80 and over , Antineoplastic Agents, Hormonal/metabolism , Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Calibration , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/metabolism , Creatinine/urine , Estrogen Antagonists/metabolism , Estrogen Antagonists/therapeutic use , Female , Humans , Middle Aged , Molecular Structure , Reproducibility of Results , Tamoxifen/metabolism , Tamoxifen/therapeutic use , Time Factors
14.
J Chromatogr A ; 914(1-2): 5-12, 2001 Apr 20.
Article in English | MEDLINE | ID: mdl-11358230

ABSTRACT

We report on the transformation of tamoxifen at 37 degrees C in synthetic gastric fluid as studied by high-performance liquid chromatography with triple quadrupole mass spectrometry. The major transformation products detected were (E)-isomer of tamoxifen, metabolite D, and several unidentified components having m/z 404. Addition of pepsin to the gastric fluid inhibited formation of all of these products. We analyzed several urine samples from breast cancer patients undergoing tamoxifen treatment. Metabolite D was identified in the urine samples and in the gastric fluid digest at a retention time of 22.0 min eluting from a reversed-phase HPLC column. Although several metabolites were found in all the urine samples of patients, some metabolites were detected in one sample but not others, suggesting tamoxifen metabolism varies in patients.


Subject(s)
Chromatography, High Pressure Liquid/methods , Estrogen Receptor Modulators/metabolism , Gastric Juice/metabolism , Tamoxifen/metabolism , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/urine , Estrogen Receptor Modulators/therapeutic use , Estrogen Receptor Modulators/urine , Humans , Spectrometry, Mass, Electrospray Ionization , Tamoxifen/therapeutic use , Tamoxifen/urine
15.
Biomed Chromatogr ; 14(3): 180-3, 2000 May.
Article in English | MEDLINE | ID: mdl-10850622

ABSTRACT

Tamoxifen is an antiestrogenic drug which is used in the treatment of breast cancer and nonmalignant breast disorders. It also has a stimulating effect on the secretion of hypofisar gonadotropic hormones and is generally used in the treatment of infertility. In males, tamoxifen causes an increase of endogenous production of androgenic steroids, and therefore is used by athletes. A method for identification of tamoxifen and metabolites in urine, using the gas chromatography and mass spectrometry system (GC/MS) is described. This study also reports the extraction methodology of tamoxifen and metabolites in urine samples of healthy male volunteers and the GC/MS conditions used to identify tamoxifen and its metabolites.


Subject(s)
Gas Chromatography-Mass Spectrometry , Tamoxifen/urine , Humans , Kinetics , Male , Tamoxifen/administration & dosage , Tamoxifen/analogs & derivatives , Tamoxifen/pharmacokinetics
16.
Cancer Chemother Pharmacol ; 42(6): 512-4, 1998.
Article in English | MEDLINE | ID: mdl-9788580

ABSTRACT

PURPOSE: To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. METHODS: A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen and metabolites were measured by high-performance liquid chromatography and compared with levels determined in 31 patients with advanced breast cancer at the steady state at a daily dose of 30 mg of tamoxifen. RESULTS: Serum and urine levels (24-h values) of tamoxifen and metabolites were lower (P < 0.05) after a loading dose than at the steady state. The difference was most pronounced for the metabolites, whereas the tamoxifen loading-dose level was near the steady state. CONCLUSION: Tamoxifen steady state can be reached in 1-2 days by the administration of a loading dose of 160 mg of tamoxifen for 2 days. Tamoxifen metabolite steady-state levels are reached regularly after 4 or more weeks during application of a loading dose. Very little tamoxifen or metabolites are excreted into the urine.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Tamoxifen/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Hormonal/blood , Antineoplastic Agents, Hormonal/urine , Breast Neoplasms/blood , Breast Neoplasms/urine , Drug Administration Schedule , Humans , Middle Aged , Tamoxifen/administration & dosage , Tamoxifen/blood , Tamoxifen/urine
17.
Drug Metab Dispos ; 21(6): 1119-24, 1993.
Article in English | MEDLINE | ID: mdl-7905393

ABSTRACT

This study describes the application of LC/MS/MS to the determination of phase I and phase II metabolites of tamoxifen in urine and plasma samples of breast cancer patients. In the plasma extracts, in addition to the parent drug and N-desmethyltamoxifen, a minor metabolite tamoxifen N-oxide was identified for the first time in human. Four intact glucuronides of tamoxifen metabolites were isolated in the 24-hr posttreatment urine sample. They were the glucuronides of 4-hydroxytamoxifen, 4-hydroxy-N-desmethyltamoxifen, dihydroxytamoxifen, and a monohydroxy-N-desmethyltamoxifen. Hydroxylation followed by glucuronidation is a well-established metabolic route of tamoxifen, and this study describes for the first time direct analyses of these metabolites in human urine samples using on-line LC tandem MS.


Subject(s)
Breast Neoplasms/metabolism , Tamoxifen/metabolism , Breast Neoplasms/blood , Breast Neoplasms/urine , Chromatography, High Pressure Liquid , Female , Humans , Mass Spectrometry , Tamoxifen/blood , Tamoxifen/urine
18.
J Chromatogr ; 565(1-2): 482-7, 1991 Apr 19.
Article in English | MEDLINE | ID: mdl-1831461

ABSTRACT

A high-performance liquid chromatographic method has been developed for the measurement of toremifene and its major human metabolites in plasma and urine. We have simplified other published methods, such that our assay uses protein precipitation in place of organic extraction, and ultraviolet detection instead of photochemical activation followed by fluorescence detection. In a stability study toremifene and metabolites remained unchanged for up to seven weeks at -70 degrees C. This simple and specific assay allowed toremifene and three metabolites to be quantitated for pharmacokinetic analyses in a high-dose Phase I trial.


Subject(s)
Chromatography, High Pressure Liquid/methods , Estrogen Antagonists/blood , Tamoxifen/analogs & derivatives , Estrogen Antagonists/pharmacokinetics , Estrogen Antagonists/urine , Fluorescence , Humans , Tamoxifen/blood , Tamoxifen/pharmacokinetics , Tamoxifen/urine , Toremifene
19.
Drug Metab Dispos ; 18(5): 645-8, 1990.
Article in English | MEDLINE | ID: mdl-1981714

ABSTRACT

Chromatographic analysis of acidic fractions of urinary radioactivity from immature female rats which had received the triarylethylene antiestrogen tamoxifen (TAM), labeled with 14C, resulted in the identification of two new metabolites. These were tamoxifen acid (TA), in which the side chain of TAM was changed to an oxyacetic acid moiety, and 4-hydroxytamoxifen acid (4-HTA), which had a similarly altered side chain plus a phenolic hydroxy group in its structure. In contrast to other TAM metabolites and other arylacetic acids, neither TA nor 4-HTA were eliminated as glucuronic acid or glycine conjugates in urine. Only small amounts of acidic radioactivity were found in liver tissue 24 and 48 hr after dosing, and none was detected in uterine tissue. However, TA plus 4-HTA accounted for 2.8% and 2.9% of the administered dose eliminated within 24 hr in urine and feces, respectively. These results suggest that TA and 4-HTA are important final products of TAM metabolism and that these, unlike other hydroxylated and/or dealkylated metabolites of this drug, may not contribute to the antiuterotrophic effects of TAM.


Subject(s)
Tamoxifen/metabolism , Animals , Chromatography, Thin Layer , Feces/chemistry , Female , Glucuronates/metabolism , Glycine/metabolism , In Vitro Techniques , Liver/metabolism , Microsomes, Liver/metabolism , Rats , Rats, Inbred Strains , Tamoxifen/analogs & derivatives , Tamoxifen/pharmacokinetics , Tamoxifen/urine , Uterus/metabolism
20.
J Chromatogr ; 497: 169-80, 1989 Dec 29.
Article in English | MEDLINE | ID: mdl-2533932

ABSTRACT

A liquid chromatographic-atmospheric pressure ionization mass spectrometric method has been developed for the analysis of toremifene metabolites in human urine after oral administration. This ionization source is a useful device for studying metabolites of toremifene because the total effluent from high-performance liquid chromatography is fed through an interface with a direct heating nebulizer and vaporizer at atmospheric pressure. To obtain good sensitivity the use of the right mobile phase is very important: ammonium acetate in methanol in the case of toremifene and its metabolites. Four unconjugated and three glucuronide-conjugated metabolites were detected in human urine. The majority of these were new and distinguishable from known metabolites.


Subject(s)
Antineoplastic Agents/metabolism , Tamoxifen/analogs & derivatives , Antineoplastic Agents/urine , Atmospheric Pressure , Breast Neoplasms/urine , Chemical Phenomena , Chemistry , Chromatography, High Pressure Liquid , Chromatography, Liquid/methods , Humans , Mass Spectrometry , Spectrophotometry, Ultraviolet , Tamoxifen/metabolism , Tamoxifen/urine , Toremifene
SELECTION OF CITATIONS
SEARCH DETAIL
...